About: Effective immunotherapy against canine visceral leishmaniasis with the FML-vaccine

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Effective immunotherapy against canine visceral leishmaniasis with the FML-vaccine Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Effective immunotherapy against canine visceral leishmaniasis with the FML-vaccine
Creator	Genaro, Odair Palatnik, Marcos Reis, Alexandre Antonio De A Trivellato, Fernando Borja-Cabrera, Cerqueira Costa, Andreia Gulnara, Patricia Hashimoto Okada, Lilian Kawasaki, A Kiyoshi, Jarbas Melo Batista, Maria Mendes, Amanda Palatnik-De-Sousa, Clarisa Paraguai De Souza, Edilma
topic	covid:d6897ab233e0b20309e0f505069be2ae020d5507#this
source	Elsevier; Medline; PMC
abstract	Abstract The potential effect of the fucose mannose ligand (FML)-vaccine on immunotherapy of canine visceral leishmaniasis was assayed on five mongrel dogs experimentally infected with Leishmania donovani and on 21 Leishmania chagasi naturally infected dogs when seropositive to FML but completely asymptomatic. The clinical signs of the experimentally infected, symptomatic dogs only disappeared after the complete vaccination. Protection was obtained in 3/5 animals that remained asymptomatic, IDR positive and parasite free, 1 year after infection. Furthermore, the asymptomatic, FML-vaccine treated dogs showed stable anti-FML IgG1 levels, increasing IgG2 levels and 79–95% of positive DTH response, during the whole experiment. Twenty-two months after complete vaccination, no obits due to visceral leishmaniasis were recorded and 90% of these dogs were still asymptomatic, healthy and parasite free. On the other hand, 37% (17/46 dogs) kala-azar obits were recorded in a control group that received no treatment during the same period, and that was FML-seropositive and asymtpomatic at the beginning of the assay. Our results indicate that the FML-vaccine was effective in the immunotherapy against visceral leishmaniasis of asymptomatic infected dogs. Normal proportions of CD4 and CD21 lymphocytes were detected in PBMC by FACS analysis, in dogs submitted to immunotherapy, suggesting their non-infectious condition. All animals showed as well significantly increased percents of CD8 lymphocytes as expected for Quillaja saponin (QuilA) vaccine treatments.
has issue date	2004-06-02(xsd:dateTime)
bibo:doi	10.1016/j.vaccine.2003.11.039
bibo:pmid	15149782
has license	els-covid
sha1sum (hex)	d6897ab233e0b20309e0f505069be2ae020d5507
schema:url	https://doi.org/10.1016/j.vaccine.2003.11.039
resource representing a document's title	Effective immunotherapy against canine visceral leishmaniasis with the FML-vaccine
has PubMed Central identifier	PMC7125925
has PubMed identifier	15149782
schema:publication	Vaccine
resource representing a document's body	covid:d6897ab233e0b20309e0f505069be2ae020d5507#body_text
is http://vocab.deri.ie/void#inDataset of	proxy:http/ns.inria.fr/covid19/d6897ab233e0b20309e0f505069be2ae020d5507
is schema:about of	named entity 'COMPLETE' named entity 'PARASITE' named entity 'CANINE VISCERAL LEISHMANIASIS' named entity 'CD8 LYMPHOCYTES' named entity 'TREATMENTS' named entity 'PERCENTS' named entity 'RECEIVED' named entity 'THESE' named entity 'CONTROL GROUP' named entity 'VACCINE' named entity 'FACS ANALYSIS' named entity 'PERIOD' named entity 'LEISHMANIA CHAGASI' named entity 'INCREASED' named entity 'MANNOSE' named entity 'HAND' named entity 'OUR' named entity 'QUILLAJA' named entity 'IGG2' named entity 'TWENTY-TWO' named entity 'dogs' named entity 'fucose' named entity 'experimentally' named entity 'naturally' named entity 'dogs' named entity 'condition' named entity 'IMMUNOTHERAPY' named entity 'CANINE VISCERAL LEISHMANIASIS' named entity 'CD4' named entity 'FML' named entity 'ANIMALS' named entity 'EFFECTIVE' named entity 'LEISHMANIA DONOVANI' named entity 'PROTECTION' named entity 'THEIR' named entity 'FML' named entity 'OBTAINED' named entity 'RECORDED' named entity 'EFFECT' named entity 'DTH' named entity 'NO TREATMENT' named entity 'SYMPTOMATIC' named entity 'INCREASING' named entity 'SEROPOSITIVE' named entity 'EXPERIMENT' named entity 'INFECTION' named entity 'ASYMPTOMATIC' named entity '90%' named entity 'DOGS' named entity 'KALA-AZAR' named entity 'DISAPPEARED' named entity 'YEAR' named entity 'BUT' named entity 'VACCINE' named entity 'PBMC' named entity 'RESPONSE' named entity 'HEALTHY' named entity 'LYMPHOCYTES' named entity 'NORMAL' named entity 'TREATED' named entity 'IMMUNOTHERAPY' named entity 'VISCERAL LEISHMANIASIS' named entity 'COMPLETELY' named entity 'SAPONIN' named entity 'VACCINATION' named entity 'STABLE'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software